15th International Symposium on Translational Research in Oncology
Please note changes have been made to the order of speakers
To Register for the 15th International Symposium on Translational Research in Oncology please click here
For printable version of programme please click here: Final Programme – 15th International Symposium on Translational Research in Oncology
FINAL PROGRAMME
Wednesday, 28th September 2022, Lansdowne Suite
09.00 – 12.30 AICRI Showcase To register for the AICRI showcase click here
Registration for symposium from 12:30 CPD: 3 external points
13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin
TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, UCLA
13:45 – 14:15 Identifying Novel Targets and Targeted Therapies for Breast Cancer
Prof. Sara Hurvitz, Professor of Medicine and Director, Breast Cancer Clinical Trials Program, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA. Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center.
14:15 – 14:45 Therapeutic Application of ADCs: Challenging the Current Breast Cancer Classification
Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston
14:45 – 15:15 Beyond ADCs – Next Generation Targeted Therapeutics
Dr. Richard Markus, President and CEO, Dantari
15:15 – 15:30 Coffee break
KEYNOTE PRESENTATION
15:30 – 16:15 Identifying Novel Targets and Targeted Therapies for Cancer
Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology and Executive Vice Chair for Research, Department of Medicine, UCLA.
TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, UCLA
16:15 – 16:45 Development of a Novel Therapeutic mAb and ADC for the Treatment of CLDN18.2-positive Cancers
Dr. Neil O’Brien, Adjunct Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA
16:45 – 17:15 Targeting Acetyl-CoA-carboxylase in breast cancer
Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program
________________________________________________
Thursday, 29th September 2022, Lansdowne Suite, Herbert Park Hotel
Registration from 08:30 CPD: 5 external points
TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto
09:00 – 09:30 Preclinical Modelling of Authentic’ Acquired Resistance to Immune Checkpoint Antibody Blockade
Professor Bob Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute University of Toronto
09:30 – 10:00 Effects of Arenaviros-based Immuno-Virotherapy on the Tumor Microenvironment (TME): Inducing Tumor-Destroying Immune Effects
Dr. Thomas Bogenrieder, CMO, Abalos Therapeutics
10:00 – 10:30 Clinical Development of Olinvacimab and PMC-403 and their Scientific Rationale
Dr. Jin-San Yoo, President & CEO, PharmAbcine, Inc
10:30 – 10:45 Coffee break
TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto
10:45 – 11:15 The Immunological Host Response to Immunotherapy: Towards Biomarker Discovery and Therapeutic Opportunities.
Prof Yuval Shaked, The Annie Chutick Chair in Medicine, Director, Rappaport-Technion-Integrated Cancer Center, Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology
11.15 – 11:45 Targeting the Metastatic Niche
Prof Janine Erler, Professor in Cancer Biology, Biotech Research and Innovation Centre, University of Copenhagen, Denmark
11:45 – 12:15 Stromal Fibroblasts Sculpt Tumour Evolution and Therapy Responses
Dr. Erik Sahai, Principal Group Leader, Assistant Research Director, The Francis Crick Institute, London
KEYNOTE PRESENTATION
12:15 – 13:00 Development of Novel Ubiquitin System-based Anti Cancer Drugs.
Prof. Aaron Ciechanover, 2004 Nobel Laureate, Distinguished Professor, Technion-Israel Institute of Technology
13:00 – 14:00 Lunch
TARGETING DIFFICULT TO DRUG GENES FOR CANCER THERAPY
Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin
14:00 – 14:30 Targeting “Undruggable” Genes: Update 2022
Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.
14:30 – 15:00 Developing a Clinically Viable MYC Inhibitor for Cancer Treatment
Prof Laura Soucek, Group Leader, Vall d’Hebron Institut d’Oncologia, ICREA Research Professor, Spain
15:00 – 15:30 Sotorasib, the First Approved KRAS Inhibitor
John Waldron, Medical Science Liaison (Haematology/Oncology), Amgen Ireland
15:30 – 15:45 Coffee break
IO THERAPIES : Session Chair – Prof John Crown, St. Vincent’s University Hospital
15:45 – 16.15 The Evolution of Neoadjuvant Immunotherapy for Lung Cancer – Translational Science to Clinical Results
Dr. Patrick Forde, Assoc Prof Oncology, Johns Hopkins University, Baltimore
16:15 – 16:45 Advances in CAR T Cell Therapies for Solid Tumors
Prof Roisin O’Cearbhaill, Research Director, Gynecologic Medical Oncology and Clinical Director, Solid Tumor Malignancies, Cellular Therapy Center, Memorial Sloan Kettering Cancer Center, New York.
16:45 – 17:15 Hepatobiliary Cancers: Clinical/ Scientific Advances and Unmet Needs
Dr. Richard Finn, Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.
_________________________________________
Friday 30th September 2022, Lansdowne Suite, Herbert Park Hotel
Registration from 8:30 CPD: 3 external points
NOVEL TARGETED DRUGS AND BIOMARKERS: Session Chair – Prof William Gallagher, University College Dublin
09:00 – 09:30 Mapping the Degradation Landscape in Cancer Reveals Insight into Anti-Tumor Immunity
Dr. Yifat Merbl, Senior Scientist, Weizmann Institute of Science, Israel
09:30 – 10:00 Clinical validation of conceptually novel anti-hypoxia A2-adenosinergic immunotherapies in cancer patients who were otherwise refractory to all other current treatments
Prof Michail Sitkovsky, E.Black Professor of Immunophysiology and Pharmaceutical Biotechnology, Director, NE Inflammation and Tissue Protection Institute Northeastern University.
10:00 – 10:30 Using the Immune System to Detect Cancer
Prof. Josh LaBaer, Executive Director, Biodesign Institute, Arizona State University
10:30 – 10:45 Coffee break
ANTIBODY DRUG CONJUGATES: Session Chair – Prof John Crown, St. Vincent’s University Hospital
10:45-11:15 Advancing Trop-2 directed ADCs into breast cancer and beyond
Dr. See Phan, VP, Clinical Research Oncology, Gilead Sciences
11:15 – 11:45Development of Antibody-Drug-Conjugates: Current and future outlook
Dr. Rodney Smith, Head of European Medical Affairs Oncology, Daiichi-Sankyo
11:45 – 12:15 Translating the Antitumor Activity of Enfortumab Vedotin to Enable a Novel Option for Patients with NMIBC
Dr. Christopher Carosino, Associate Director Toxicology, PADCEV Translational Sciences Lead, Investigative Toxicology Group Lead
12:15 – 13:15 Lunch
CANCER IMMUNOTHERAPY I: Session Chair – Prof. Mario Sznol, Yale
13:15 – 13:45 The Future of Immunotherapy in Melanoma: LAG-3 and Beyond
Dr. Giuseppe Gullo, Sr. Director, Clinical Sciences, Oncology, Regeneron
13:45 – 14:15 Bench to Bedside Trials in Uveal Melanoma at Sylvester Cancer Center
Dr. Jose Lutzky, Leader, Cutaneous and Ocular Oncology Site Disease Group
Medical Director, Clinical Trials Office, Professor of Clinical Medicine, University of Miami Sylvester Comprehensive Cancer Center.
14:15 – 14:45 Topic: Identifying new targets and how to identify new ImmTAX
Dr. Peter Molloy, Director of Protein Engineering in Research, Immunocore
14:45 – 15:00 Coffee break
CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale
15:00 – 15:30 Anti-CD47 plus Trastuzumab Induces Pacrophage phagocytosis (ADCP) of HER2-positive Breast Cancer Cells selected for Tolerance to Mrastuzumab-mediated ADCC.
Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine
15:30 – 16:00 Results of a RCT phase 3, comparing ipilimumab with TIL therapy for advanced stage melanoma having failed anti-PD-1
Prof. Dr. John. B.A.G. Haanen, Medical Oncology Department, Netherlands Cancer Institute
16:00 – 16:30 Designing and delivering next-generation TCR T-cell therapies
Dr. Joanna Brewer, Chief Scientific Officer, Adaptimmune LLC
16:30 – 17:00 Topic: Il-2 ortholog
Dr. Martin Oft, Chief Development Officer, Synthekine
Meeting Ends
